A series of imidazo[1,2-a]pyridine analogs that effectively inhibit cholesterol 24-hydroxylase (CYP46A1) was reported in WO2014061676. The treatment or prophylaxis of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease, by these novel CYP46A1 inhibitors is claimed in the patent. These compounds represent a novel pharmacophore that is different from other structural motifs described in the prior patent publications by Takeda Pharmaceutical Company Ltd.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543776.2014.989214 | DOI Listing |
Publication Analysis
Top Keywords
cholesterol 24-hydroxylase
8
24-hydroxylase cyp46a1
8
cyp46a1 inhibitors
8
imidazo[12-a]pyridines cholesterol
4
inhibitors patent
4
patent evaluation
4
evaluation wo2014061676
4
wo2014061676 series
4
series imidazo[12-a]pyridine
4
imidazo[12-a]pyridine analogs
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!